Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

@article{Kip2013TumorNF,
  title={Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.},
  author={Kevin E. Kip and Jason M. Swoger and Lisa M. Grandinetti and Arthur M. Barrie and Julia B. Greer and Miguel D. Regueiro},
  journal={Inflammatory bowel diseases},
  year={2013},
  volume={19 6},
  pages={1164-72}
}
BACKGROUND Crohn's disease (CD) is a chronic inflammatory, relapsing, and progressive condition that leads to bowel damage and subsequent stricturing or penetrating complications. Tumor necrosis factor (TNF) α antagonists (e.g., infliximab) can achieve sustained remission in CD. However, a paradox exists as to whether use of these medications, which… CONTINUE READING